Bottom line
PRHSX vs JDOC: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and JDOC (JPMorgan Healthcare Leaders ETF) share a meaningful slice of their top holdings — about 58% by weight.
But PRHSX is far broader, holding 279 positions to 61 for JDOC, so beyond the top names it adds exposure JDOC doesn't have.
JDOC is cheaper at 0.65% vs 0.83% — a difference of $18 a year per $10,000 invested.
Over one year, PRHSX returned +17.7% vs +14.9% for JDOC.
Updated Nov 19, 2026
PRHSX vs JDOC side by side
| PRHSX | JDOC | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | T. Rowe Price | J.P. Morgan |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 0.65% |
| Annual cost per $10k | $83 | $65 |
| 10-yr cost on $10k (prospectus) | $1,025 | $810 |
| Max front load | — | None |
| 12b-1 fee | — | — |
| 1-yr return | +17.7% | +14.9% |
| 5-yr return (annualized) | +4.2% | — |
| 10-yr return (annualized) | +9.1% | — |
| Best quarter | +23.5% | +11.3% |
| Worst quarter | −15.8% | −11.9% |
| Net assets (fund) | $11.9B | $9.1M |
| Number of holdings | 279 | 61 |
| Portfolio turnover | 62% | 92% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | JDOC | Difference |
|---|---|---|---|
| 2025 | +17.7% | +14.9% | +2.8% |
| 2024 | +1.8% | −0.6% | +2.5% |
Source: Fund prospectus bar charts
Holdings overlap
13 of PRHSX's top 25 holdings also appear in JDOC's top 25.
| Holding | PRHSX | JDOC |
|---|---|---|
| Eli Lilly & Co | 14.28% | 7.76% |
| Johnson & Johnson | 6.63% | 4.82% |
| Unitedhealth Group Inc | 5.99% | 5.85% |
| Abbvie Inc | 5.10% | 7.85% |
| Merck & Co. Inc. | 4.01% | 4.82% |
| Thermo Fisher Scientific Inc | 2.52% | 3.73% |
| Bristol-myers Squibb Co | 2.11% | 3.57% |
| Abbott Laboratories | 1.89% | 3.11% |
| Intuitive Surgical Inc | 1.87% | 1.93% |
| Stryker Corp | 1.78% | 2.23% |
| Danaher Corp | 1.43% | 2.16% |
| Cardinal Health Inc | 1.03% | 1.51% |
| Cvs Health Corp | 0.94% | 2.83% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
FAQ
What is the difference between PRHSX and JDOC?
Which is cheaper, PRHSX or JDOC?
Should I own both PRHSX and JDOC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.